# Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs

> **NIH NIH R34** · UNIVERSITY OF WASHINGTON · 2021 · $214,590

## Abstract

ABSTRACT/PROJECT SUMMARY
The opioid epidemic is a major public health crisis in the United States, leading to substantial morbidity and
mortality related to the consequences of opioid use disorders and injection drug use, namely hepatitis C virus
(HCV), HIV, and overdose. Yet, we are at a unique historical moment, as we possess effective medications
that can improve and sustain the lives of people who inject drugs (PWID). Currently there are medications that
can be prescribed to 1) cure HCV (directly-acting antivirals or DAAs), 2) prevent HIV infection (Pre-exposure
Prophylaxis [PrEP]), and 3) treat/prevent overdose (naloxone and medications to treat OUD). Furthermore,
there is an unprecedented opportunity to eliminate HCV, a disease that is transmitted through injecting drugs.
However, achieving the goals of elimination will require better systems for allowing PWID access to
medications to cure hepatitis C, as well as medications to prevent overdose and HIV. Pharmacists and
community-pharmacy programs may be an innovative solution for this problem. Collaborative Drug Therapy
Agreements (CDTAs) allow pharmacists to have authority to autonomously perform testing and prescribing and
dispensing medications. We propose to use this R34 mechanism to develop and pilot test a novel health
service delivery model, namely a community-pharmacy program for providing DAAs and medications to
prevent overdose and HIV among PWID with HCV. For Aim #1, we will conduct qualitative interviews with
PWID with HCV and other key community stakeholders in order to inform the development of a community-
pharmacy program to expand access to medications to treat HCV and prevent overdose and HIV. For Aim #2,
we will pilot and evaluate the community-pharmacy program at a local pharmacy in Seattle. This application is
submitted under the funding announcement PA-18-774 (“Pilot Health Services and Economic Research on the
Treatment of Drug, Alcohol, and Tobacco Abuse”), which includes pilot testing of health service interventions
that optimize access utilization of drug use disorder related services, as well as services for comorbid medical
conditions. The proposed research leverages a number of existing community partnerships with local
stakeholders and would lead to a future multi-site effectiveness study that would utilize existing community-
based pharmacies in order to work toward improving drug users' health by expanding access to life-saving
medications.

## Key facts

- **NIH application ID:** 10197864
- **Project number:** 5R34DA047660-03
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Judith Tsui
- **Activity code:** R34 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $214,590
- **Award type:** 5
- **Project period:** 2019-08-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10197864

## Citation

> US National Institutes of Health, RePORTER application 10197864, Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs (5R34DA047660-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10197864. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*